NASDAQ:ARDS - Aridis Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
Get Started
$9.32 +0.05 (+0.54 %)
(As of 05/27/2019 06:00 AM ET)
Previous Close$9.32
Today's Range$9.32 - $9.41
52-Week Range$7.59 - $13.85
Volume1,399 shs
Average Volume1,920 shs
Market Capitalization$75.59 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Aridis Pharmaceuticals (NASDAQ ARDS) News Headlines

Source:
DateHeadline
Aridis Pharmaceuticals (ARDS) Given a $25.00 Price Target by Maxim Group AnalystsAridis Pharmaceuticals (ARDS) Given a $25.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - May 17 at 10:41 PM
Aridis Pharmaceuticals Announces First Quarter 2019 ResultsAridis Pharmaceuticals Announces First Quarter 2019 Results
finance.yahoo.com - May 15 at 11:32 AM
Aridis Pharmaceuticals (ARDS) Releases Earnings Results, Misses Estimates By $0.12 EPSAridis Pharmaceuticals (ARDS) Releases Earnings Results, Misses Estimates By $0.12 EPS
www.americanbankingnews.com - May 15 at 8:42 AM
Analysts Anticipate Aridis Pharmaceuticals Inc (ARDS) Will Post Earnings of -$0.82 Per Share Analysts Anticipate Aridis Pharmaceuticals Inc (ARDS) Will Post Earnings of -$0.82 Per Share
www.americanbankingnews.com - May 11 at 7:03 AM
Aridis Pharmaceuticals Inc (ARDS) Given Average Recommendation of "Buy" by AnalystsAridis Pharmaceuticals Inc (ARDS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 7 at 4:51 AM
Will Aridis Pharmaceuticals Continue to Surge Higher?Will Aridis Pharmaceuticals Continue to Surge Higher?
www.nasdaq.com - April 3 at 9:08 AM
Aridis Pharmaceuticals (ARDS) Upgraded to Buy: Heres WhyAridis Pharmaceuticals (ARDS) Upgraded to Buy: Here's Why
www.nasdaq.com - April 2 at 9:12 PM
Aridis Pharmaceuticals (ARDS) Upgraded to Buy: Here's WhyAridis Pharmaceuticals (ARDS) Upgraded to Buy: Here's Why
finance.yahoo.com - April 2 at 12:27 PM
Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business UpdateAridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update
finance.yahoo.com - March 29 at 12:33 PM
Stocks To Watch: Those Ticking ClocksStocks To Watch: Those Ticking Clocks
seekingalpha.com - February 9 at 10:37 AM
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Has Attractive FundamentalsAridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Has Attractive Fundamentals
finance.yahoo.com - January 31 at 3:34 PM
AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis PatientsAR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients
finance.yahoo.com - December 12 at 8:34 AM
Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program DesignationsAridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations
finance.yahoo.com - December 4 at 3:22 PM
Aridis Pharmaceuticals Inc (ARDS.OQ)Aridis Pharmaceuticals Inc (ARDS.OQ)
www.reuters.com - November 13 at 3:21 PM
Aridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate OverviewAridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate Overview
finance.yahoo.com - November 13 at 3:21 PM
Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine"Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine"
finance.yahoo.com - November 7 at 3:19 PM
Aridis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare ConferenceAridis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
finance.yahoo.com - September 26 at 3:16 PM
Aridis Pharmaceuticals issues additional broad patent for AR-201and AR-401Aridis Pharmaceuticals issues additional broad patent for AR-201and AR-401
seekingalpha.com - September 24 at 3:16 PM
Aridis Pharmaceuticals Strengthens Intellectual Property Portfolio With Additional Broad Patent Coverage For Multiple Product CandidatesAridis Pharmaceuticals Strengthens Intellectual Property Portfolio With Additional Broad Patent Coverage For Multiple Product Candidates
finance.yahoo.com - September 24 at 3:16 PM
Laidlaw Starts Aridis Pharmaceuticals (ARDS) at BuyLaidlaw Starts Aridis Pharmaceuticals (ARDS) at Buy
www.streetinsider.com - September 20 at 3:15 PM
Northland Starts Aridis Pharmaceuticals (ARDS) at OutperformNorthland Starts Aridis Pharmaceuticals (ARDS) at Outperform
www.streetinsider.com - September 12 at 3:15 PM
Aridis Pharmaceuticals Announces Pricing of Initial Public OfferingAridis Pharmaceuticals Announces Pricing of Initial Public Offering
finance.yahoo.com - September 10 at 1:25 PM
This page was last updated on 5/27/2019 by MarketBeat.com Staff

Featured Article: Compound Interest
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel